Just weeks after completing a deal to buy Bone Care International for $719 million, Genzyme announced it will hand out pink slips to about 40 employees. Most of the workers had been employed in various administrative duties. Genzyme says it plans to retain Bone Care's laboratory facility and most of its scientists. Bone Care sold a drug that restores kidney patients' vitamin D levels.
- read this report in the Milwaukee Journal-Sentinel for more